Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

[1]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[2]  Heather L. Mulder,et al.  The genomic landscape of core-binding factor acute myeloid leukemias , 2016, Nature Genetics.

[3]  K. Döhner,et al.  All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study , 2016, Annals of Hematology.

[4]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[5]  O. Abdel-Wahab,et al.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.

[6]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[7]  H. Dombret,et al.  Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial , 2015, Haematologica.

[8]  Li-li Wang,et al.  High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia , 2015, PloS one.

[9]  C. Bloomfield,et al.  Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) , 2014 .

[10]  R. Greil,et al.  Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. , 2014, Blood.

[11]  Qiaojun He,et al.  Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. , 2014, Biochemical pharmacology.

[12]  K. Döhner,et al.  Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? , 2013, Hematology. American Society of Hematology. Education Program.

[13]  M. Gertz,et al.  Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases , 2013 .

[14]  Cedric E. Dos Santos,et al.  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. , 2013, Blood.

[15]  R. Hills,et al.  The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia , 2013, Leukemia.

[16]  Qiaojun He,et al.  MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia , 2013, PloS one.

[17]  L. Bullinger,et al.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). , 2013, Blood.

[18]  Augustin Ferrant,et al.  Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.

[19]  M. Colombo,et al.  Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors , 2011, Oncogene.

[20]  Chuanfeng Wu,et al.  C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice , 2011, Proceedings of the National Academy of Sciences.

[21]  Franz Király,et al.  Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Lübbert,et al.  Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib , 2010, Leukemia.

[23]  J. Pollack,et al.  KIT mutations confer a distinct gene expression signature in core binding factor leukaemia , 2010, British journal of haematology.

[24]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[25]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Fröhling,et al.  Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia , 2004, Leukemia.

[27]  K. Döhner,et al.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[29]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[30]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[32]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[33]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[34]  I. Weissman,et al.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Lisa Garrett,et al.  The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia , 1999, Nature Genetics.

[36]  J. Downing,et al.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. , 1998, Blood.

[37]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.

[38]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  C. Bloomfield,et al.  Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia , 2016 .

[41]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[42]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[43]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .